The good news in the UnitedHealth exchange departures; House Dems voice support for Part B demo

News From Around the Web

> UnitedHealth's exit from most Affordable Care Act exchanges, rather than a sign of the marketplace's demise, actually reflects positive features of the healthcare reform law, such as increased competition among insurance companies, according to an editorial from The Washington Post. Editorial

> Twenty House Democrats have voiced their support for the Obama administration's controversial Part B payment demonstration, The Hill reports, going against Democratic members of the Senate Finance Committee who have signed letters criticizing the proposal. Article

> A new study from the Urban-Brookings Tax Policy Center and the Urban Institute Health Policy Center examines the implications of Bernie Sanders' economic plan, finding that federal spending on acute care would rise by $29 trillion and saying "its cost would significantly exceed the revenues raised by his tax plan." Study

Health Finance News

> Hospitals optimally want to have some control over their payer mix, but the matter is often out of their hands. The location of the hospital plays a big part in its payer mix, as well as other circumstances that drive patients into its beds, according to Healthcare Finance News. Article

> Many pharmaceutical manufacturers have raised their prices so much on drugs that have inched toward their patent expiration that there is less incentive for generic or biosimilar manufacturers to offer a drastically reduced price, according to The Wall Street Journal. Article

And Finally… Not getting that security deposit back. Article

Suggested Articles

Insurance company Oscar hired former Uber talent as its chief executive officer, Jonathan Bush gets a new gig at Firefly Health and more.

Fourteen doctors and other medical professionals were among those charged in fraud cases that totaled $258 million in California, Oregon, and Arizona.

House Speaker Nancy Pelosi released a plan to give Medicare the power to negotiate for lower drug prices, but will it get out of Congress?